These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22101248)

  • 1. Proteasome inhibitor bortezomib (PS-341) enhances RANKL-induced MDA-MB-231 breast cancer cell migration.
    Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Liu Y; Qu X
    Mol Med Rep; 2012 Feb; 5(2):580-4. PubMed ID: 22101248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation.
    Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
    Oncol Rep; 2011 Nov; 26(5):1243-50. PubMed ID: 21725611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
    Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
    Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.
    Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
    Biochem Biophys Res Commun; 2011 May; 408(3):411-6. PubMed ID: 21514280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.
    Tsubaki M; Komai M; Fujimoto S; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
    J Exp Clin Cancer Res; 2013 Sep; 32(1):62. PubMed ID: 24011086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
    Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
    Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BU-32: a novel proteasome inhibitor for breast cancer.
    Agyin JK; Santhamma B; Nair HB; Roy SS; Tekmal RR
    Breast Cancer Res; 2009; 11(5):R74. PubMed ID: 19821999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
    Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY
    J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
    Zhang L; Teng Y; Fan Y; Wang Y; Li W; Shi J; Ma Y; Li C; Shi X; Qu X; Liu Y
    Oncotarget; 2015 Sep; 6(26):22918-33. PubMed ID: 26087197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway.
    Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
    Oncol Lett; 2012 Feb; 3(2):395-400. PubMed ID: 22740919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer.
    Wang J; Liu Y; Wang L; Sun X; Wang Y
    Oncotarget; 2016 Feb; 7(5):5564-75. PubMed ID: 26734994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib inhibits human osteoclastogenesis.
    von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
    Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
    Sheng L; Wu CY; Chen XF
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.